Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGER | Q15109 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 7/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | NPY1R | P25929 | 1/20 | 0.49 |
| ▸ | NPY2R | P49146 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | DRD4 | P21917 | 2/20 | 0.46 |
| ▸ | DRD3 | P35462 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14490855 | 0.89 | AGER (0.60) | AGERHTTHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL133355 | 0.88 | AGER (0.58) | AGERHTTHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL130152 | 0.88 | HTT (0.72) | AGERHTTHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL10785852 | 0.86 | AGER (0.45) | AGERHTTHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL14490806 | 0.85 | HTT (0.60) | AGERHTTHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL20920574 | 0.85 | AGER (0.62) | AGERHTTHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL9730411 | 0.83 | LMNA (0.61) | AGERHTTALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL11383600 | 0.83 | MEN1 (0.44) | AGERHTTALDH1A1LMNAMAPT | |
| SCHEMBL11179877 | 0.82 | HTT (0.51) | AGERHTTHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL10827981 | 0.81 | HTT (0.56) | AGERHTTHPGDALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135641-A1 | Synthesis | PALMER RICHARD M J | 2007-06-14 | — | — | US | disclosed |
| US-20070135641-A1 | Synthesis | PALMER RICHARD M J | 2007-06-14 | — | — | US | disclosed |
| US-7189852-B2 | Preparing renzapride (hydrochloride) on a laboratory or industrial scale by a simplified process of forming the acyl chloride derivative of 2-(methoxy),3-acyamino,5-chlorobenzoic acid by reacting oxalyl or thionyl chloride in a solvent, e.g. dimethylformamide; coupling with 1-diazabicylo(3.3.1)nonane | ALIZYME THERAPEUTICS LIMITED (GB) | 2007-03-13 | — | — | US | disclosed |
| US-7189852-B2 | Preparing renzapride (hydrochloride) on a laboratory or industrial scale by a simplified process of forming the acyl chloride derivative of 2-(methoxy),3-acyamino,5-chlorobenzoic acid by reacting oxalyl or thionyl chloride in a solvent, e.g. dimethylformamide; coupling with 1-diazabicylo(3.3.1)nonane | ALIZYME THERAPEUTICS LIMITED (GB) | 2007-03-13 | — | — | US | disclosed |
| EP-0550550-B1 | 3,9-DIAZABICYCLO (3.3.1) NONAN-7-YL DERIVATIVES, PROCESS AND INTERMEDIATES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BEECHAM GROUP PLC (GB) | 2003-07-16 | — | — | EP | disclosed |
| US-6110934-A | Substituted benzamide derivatives and their use as anticonvulsants | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-08-29 | — | — | US | disclosed |
| EP-0906283-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 1999-04-07 | — | — | EP | disclosed |
| WO-1997048683-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 1997-12-24 | — | — | WO | disclosed |
| EP-0481756-B1 | Benzamide derivatives | TEIKOKU CHEM IND CO LTD (JP) | 1997-07-09 | — | — | EP | disclosed |
| US-5237066-A | Reacting quinuclidone with (R)-alpha-methylbenzylamine; reduction with alkali metal borohydride; hydrogenolysis in acid | DELANDE S.A. (FR) | 1993-08-17 | — | — | US | disclosed |
| US-4329344-A | 4-(Phenylalkyl)piperazine-1-carboxamides | BEECHAM GROUP LIMITED (GB) | 1982-05-11 | — | — | US | disclosed |
| EP-0047620-A1 | Aryl diazabicyclyl amides, a process for their preparation and use | BEECHAM GROUP PLC (GB) | 1982-03-17 | — | — | EP | disclosed |
| EP-0034015-A2 | Pharmaceutically active compounds | BEECHAM GROUP PLC (GB) | 1981-08-19 | — | — | EP | disclosed |
| US-4273778-A | TREATMENT OF GASTROINTESTINAL DISORDERS, NERVOUS SYSTEM DISORDERS, AND PSYCHOLOGICAL DISORDERS | BEECHAM GROUP, LIMITED (GB) | 1981-06-16 | — | — | US | disclosed |
| US-4267175-A | FOR USE AS AN ANTIEMETIC, AND TREATMENT FOR GASTROINTESTINAL DISORDERS | BEECHAM GROUP LIMITED (GB) | 1981-05-12 | — | — | US | disclosed |
| US-4223034-A | TRANQUILIZERS | BEECHAM GROUP LIMITED (GB) | 1980-09-16 | — | — | US | disclosed |
| US-4213983-A | Treating gastro-intestinal disorders and emesis with n-(heterocyclic substituted) benzamides | BEECHAM GROUP LIMITED (GB) | 1980-07-22 | — | — | US | disclosed |
| EP-0013138-A1 | Azabicycloalkyl derivatives, a process for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1980-07-09 | — | — | EP | disclosed |
| US-4163789-A | Anti-psychotic (cycloalkenylalkylpiperidino) benzamides | ANPHAR, S.A. (ES) | 1979-08-07 | — | — | US | disclosed |
| US-4138492-A | FOR TREATMENT OF GASTROINTESTINAL DISORDERS | ANPHAR, S.A. (ES) | 1979-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135641-A1 | Synthesis | ALKBH5, AZI2, ALKBH1 | AGER 4101/4885HTT 1816/4885HPGD 2216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.